Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; and The University of Texas MD Anderson Cancer Center. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000
Debt
Debt-to-Equity Ratio2.03
Current Ratio3.39
Quick Ratio3.12
Price-To-Earnings
Trailing P/E Ratio16.04
Forward P/E Ratio14.39
P/E Growth1.97
Sales & Book Value
Annual Sales$22.85 billion
Price / Sales5.72
Cash Flow$15.3577 per share
Price / Cash13.14
Book Value$34.77 per share
Price / Book5.80
Profitability
EPS (Most Recent Fiscal Year)$12.58
Net Income$1.98 billion
Net Margins10.19%
Return on Equity43.18%
Return on Assets12.70%
Miscellaneous
Employees20,800
Outstanding Shares647,270,000
Market Cap$131.21 billion
Amgen (NASDAQ:AMGN) Frequently Asked Questions
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Tuesday, July 31st. Shareholders of record on Friday, August 17th will be paid a dividend of $1.32 per share on Friday, September 7th. This represents a $5.28 dividend on an annualized basis and a yield of 2.62%. The ex-dividend date of this dividend is Thursday, August 16th. View Amgen's Dividend History.
How will Amgen's stock buyback program work?
Amgen announced that its Board of Directors has initiated a stock repurchase plan on Friday, February 2nd 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its shares are undervalued.
How were Amgen's earnings last quarter?
Amgen, Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Thursday, July, 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.52 by $0.31. The medical research company earned $6.06 billion during the quarter, compared to analyst estimates of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The company's revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.27 earnings per share. View Amgen's Earnings History.
When is Amgen's next earnings date?
How can I listen to Amgen's earnings call?
Amgen will be holding an earnings conference call on Tuesday, October 30th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8558554105.
What guidance has Amgen issued on next quarter's earnings?
Amgen issued an update on its FY18 earnings guidance on Thursday, July, 26th. The company provided earnings per share guidance of $13.30-14.00 for the period, compared to the Thomson Reuters consensus estimate of $13.74. The company issued revenue guidance of $22.5-23.2 billion, compared to the consensus revenue estimate of $22.77 billion.
What price target have analysts set for AMGN?
21 analysts have issued twelve-month price targets for Amgen's shares. Their forecasts range from $179.00 to $229.00. On average, they anticipate Amgen's share price to reach $204.6195 in the next year. This suggests a possible upside of 1.4% from the stock's current price. View Analyst Price Targets for Amgen.
What is the consensus analysts' recommendation for Amgen?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 12 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amgen.
What are Wall Street analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. Cann analysts commented, "The FDA approval of this sNDA for Kyprolis based on the positive A.R.R.O.W. data supports our outlook that Kyprolis will have increased adoption and greater market penetration over the next five years. The A.R.R.O.W. results support a nearly 28% increase in volume of Kyprolis administered per patient in the RRMM setting. We anticipate Kyprolis sales will increase to $2.0 billion in 2022 from $835 million in 2017 and will account for 6.2% of sales, being the fourth-largest driver of sales growth. Continuing positive data, like those demonstrated in A.R.R.O.W., ASPIRE and ENDEAVOR, along with label expansions to include overall survival in the relapsed multiple myeloma setting, support this outlook that Kyprolis will have increased adoption and greater market penetration over the next five years." (10/1/2018)
- 2. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Repatha, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the recent approval of migraine candidate, Aimovig was a huge boost. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given the slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions." (10/1/2018)
- 3. JPMorgan Chase & Co. analysts commented, "AMGN’s top-line continues to be uninspiring, but the bottom line will meaningfully benefit from a lower than expected tax rate (surprise, surprise) and a large, accelerated $10B share buyback. There are several moving pieces to consider heading into 2018 (which are apparent in management’s uncharacteristically wide guidance range), including timing/magnitude of legacy franchise erosion (e.g., Neulasta & Sensipar), trajectory of recent/upcoming launches (e.g., Kyprolis, Repatha, Aimovig), and the extent to which AMGN chooses to exercise its upsized share repurchase authorization (now ~$14B in total). While we continue to be keenly interested in potential for M&A (which AMGN continues to be constructive on) and the earlier stage pipeline, we maintain our Neutral rating pending evidence of sustainable near-/mid-term growth." (2/4/2018)
- 4. Mizuho analysts commented, "We expect Q4 ’17 trends for both unit demand and net selling price to continue into 2018 – Expect Q1 ’18 sales to be ~ 20% of full year 2018 sales Neulasta US = 969 / 950 / 949 Neulasta Ex-US = 145 / 151 / 152 Neulasta WW = 1114/ 1103 / 1100 Neupogen US = 82 / 87 / 87 PLEASE REFER TO PAGE 5 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (2/1/2018)
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Gilead Sciences (GILD), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Aerie Pharmaceuticals (AERI), Halozyme Therapeutics (HALO), Repligen (RGEN) and China Biologic Products (CBPO).
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Mr. Robert A. Bradway, Chairman & CEO (Age 55)
- Mr. David W. Meline, Exec. VP & CFO (Age 61)
- Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 57)
- Dr. Sean E. Harper, Non-Exec. Officer (Age 55)
- Mr. Esteban Santos, Exec. VP of Operations (Age 50)
Who are Amgen's major shareholders?
Amgen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.36%), Aperio Group LLC (0.07%), Gateway Investment Advisers LLC (0.06%), Nisa Investment Advisors LLC (0.06%), Strs Ohio (0.05%) and First Manhattan Co. (0.05%). Company insiders that own Amgen stock include Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Institutional Ownership Trends for Amgen.
Which major investors are selling Amgen stock?
AMGN stock was sold by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, Strs Ohio, First Manhattan Co., Oakbrook Investments LLC, MERIAN GLOBAL INVESTORS UK Ltd, Huntington National Bank, Beacon Financial Group and State of New Jersey Common Pension Fund D. Company insiders that have sold Amgen company stock in the last year include Carbonnel Francois De and Sean E Harper. View Insider Buying and Selling for Amgen.
Which major investors are buying Amgen stock?
AMGN stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Barometer Capital Management Inc., Nisa Investment Advisors LLC, American Financial Network Advisory Services LLC, First Hawaiian Bank, Aperio Group LLC, Personal Capital Advisors Corp and Canton Hathaway LLC. View Insider Buying and Selling for Amgen.
How do I buy shares of Amgen?
Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of AMGN stock can currently be purchased for approximately $201.80.
How big of a company is Amgen?
Amgen has a market capitalization of $131.21 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $12.58 on an earnings per share basis. Amgen employs 20,800 workers across the globe.
What is Amgen's official website?
How can I contact Amgen?
Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]
MarketBeat Community Rating for Amgen (NASDAQ AMGN)
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
